



HANSA BIOPHARMA

COMPANY FACTS

Founded	2007
Stock Exchange	NASDAQ Stockholm (HANSA)
Headquarter	Lund, Sweden
Operations	Europe and the US
Employees	145 (~2/3 in R&D)
Key Executives	Peter Nicklin, Chairman Søren Tulstrup, President & CEO Donato Spota, SVP & CFO Christian Kjellman, SVP & CSO/COO

MARKET DATA (Q2 2022)

Market Cap	USD ~220m
52 Week Range	SEK 47-152
Avg. Daily Turnover	vol. 275k shares
Shares Outstanding	45m
Top 5 Shareholders	Redmile Group 12.1% AP4 4.9% NXT2B 4.8% Invesco 4.4% Thomas Olausson 4.1%

STOCK CHART (1Y)



KEY FINANCIALS

SEKm	2019	2020	2021
Revenue	3m	6m	34m
R&D cost	-193m	-227m	-231m
Net loss	-360m	-421m	-548m
Cash & Short investment	601m	1,378m	889m
Operating Cash Flow	-335m	-290m	-481m
Employees	74	87	133

* Unaudited

CALENDAR

Aug 9, 2022	BTIG Biotechnology Conference 2022
Aug 10, 2022	Kempen US non-deal road show
Aug 11, 2022	Canaccord Annual Growth Conference
Aug 18, 2022	Penserpodden "Focus on autoimmunity"
Aug 24, 2022	Handelsbanken Life Science Day
Aug 31, 2022	Redeye Late-stage Life Science conference
Sept 7, 2022	Pareto annual Healthcare Conference 2022
Sept 8, 2022	Citi's 17th Annual BioPharma Conference
Sept 12, 2022	H.C. Wainwright Global Investment Conf
Sept 13-14, 2022	MorganStanley Global Healthcare Conf

CONTACTS

Klaus Sindahl Head of Investor Relations M: +46(0)709-298 269 klaus.sindahl@hansabiopharma.com	Katja Margell Head of Corp. Comms. M: +46(0)768-198 326 katja.margell@hansabiopharma.com
---	---

...at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...

ABOUT HANSA BIOPHARMA

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitized patients. The Company has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S.

BROAD PIPELINE IN TRANSPLANTATION AND AUTOIMMUNE DISEASES


Candidate	Indication	Research/ Preclinical	Phase 1	Potentially Pivotal program/ Phase 2	Phase 3	Marketing Authorization	Marketed
	US Kidney transplantation in highly sensitized patients ^{1,2}	Completed	Completed	Completed	Ongoing		
	Anti-GBM antibody disease (investigator-initiated study)	Completed	Completed	Completed	Planned		
	Antibody mediated kidney transplant rejection (AMR)	Completed	Completed	Completed	Ongoing		
	GBS (Guillain Barre Syndrome)	Completed	Completed	Completed	Ongoing		
	Limb-Girdle (LGMD) & Duchenne (DMD) (Pre-treatment ahead of gene therapy with Sarepta)	Ongoing					
	Pompe disease (Pre-treatment ahead of gene therapy with AskBio)	Ongoing					
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology	Ongoing					
EnzE	Cancer immunotherapy	Ongoing					

- Completed ¹ Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)
- Ongoing ² Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
- Planned ³ Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund
- ^{*)} The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients. A post-approval study will commence in parallel with the launch

STRATEGIC PRIORITIES




ANTICIPATED FUTURE MILESTONES



IMLIFIDASE – A NOVEL APPROACH TO ELIMINATING PATHOGENIC IgG


Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection




Imlifidase, a unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab)₂ fragment and one homo-dimeric Fc-fragment




Imlifidase inactivates IgG in 2-6 hours


- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



OUR BUSINESS MODEL



Potential indication universe



* The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients.

** In the US a new study has commenced targeting a BLA filing by H1 2024